Abstract Genome-wide association studies (GWAS) in cancer have successfully identified over 450 regions that harbor susceptibility alleles with small effects contributing to the risk of one or more cancers. Less than 10 % of the regions identified thus far are common to more than one cancer, but it is these regions which display pleiotropy that are especially informative and provide new opportunities to gain insights into common mechanisms of carcinogenesis. Since the GWAS age has been notable for scalability, large-scale consortia have successfully combined many studies to identify novel regions associated with risk for cancer. In fact, for common cancers, a substantial fraction of markers for common alleles have been identified, and additional studies of the cumulative "polygenic" effect of large scans further suggest that many additional alleles remain to be characterized. The emerging catalog of common variants, which represents a fraction of the underlying genetic architecture of cancer susceptibility, already constitutes a set for common cancers that could be used in stratification and public health measures. On the other hand, the discovery of many regions is occurring at a rate that exceeds our capacity to understand the underlying biology contributing to each risk allele. Nearly all susceptibility regions harbor one or more variants that point towards changes in the regulation of key genes and pathways and not protein coding changes resulting in Bdrivers^of somatic alterations. Further investigation of each region depends upon the sequence of fine mapping (e.g., identification of correlated variants) using in silico functional tools to nominate the most promising variants for detailed laboratory follow-up studies. Each region has to be interrogated individually, taking into account the unique features of each genomic locale in order to understand the biological underpinnings of the susceptibility variants. Building a comprehensive catalog of susceptibility alleles, across a spectrum of frequencies and effect sizes, and functional annotation of these should be instrumental in revealing new cancer biology and eventually used in precision prevention.
Introduction
In the last 25 years, cancer susceptibility alleles have been discovered by a progression of study designs, beginning with linkage analyses in cancer-laden families through the largely unsuccessful world of candidate genetic association studies to the success of genome-wide association studies (GWAS) and, more recently, next-generation sequencing (NGS) of high-risk families. All but the last approach has been predicated on achieving statistical evidence using either linkage or association analyses [1] . The early findings of NGS have required laboratory corroboration, primarily to bolster the smaller sample sizes analyzed, particularly in search of less common variants with a moderate effect-one not seen in linkage and too rare for coverage using current GWAS microarrays [2] . The This article is part of the Topical Collection on Genetic Epidemiology tools used in the cancer genetic susceptibility mapping have mirrored the above and been derived from the annotation of the human genome sequence, shifting from genotyping single tandem repeats (STRs) and single nucleotide polymorphisms (SNPs) to typing hundreds of thousands of SNPs in parallel using microarray technologies and recently to whole genome sequence analysis using massive parallel sequencing technologies.
Initially, linkage analysis is conducted in family studies, notable for multiple members who have developed the same type of cancer and has provided the first evidence for high penetrance rare mutations; these studies used polymorphic genome-wide microsatellite markers to detect segregating haplotypes within a family structure [3, 4] . Follow-up sequence analysis of many possible genes was required within the identified linkage peaks, and yet only a small proportion of causative mutations have been characterized. These rare or uncommon mutations with large effect sizes ( Fig. 1) were particularly found in families with extensive breast and colorectal cancer, melanoma, or a constellation of cancers, such as Li-Fraumeni Syndrome [5] [6] [7] [8] [9] [10] . A high fraction of these overlap with driver mutations, identified in the Cancer Genome Atlas and COSMIC databases, underscoring the importance of the altering the germline as well as the somatic genome [11•, 12] .
Over time, investigators turned to candidate gene association studies, since it was argued that linkage analysis for complex diseases would be less efficient than association analyses in populations for mapping the set of common variants with smaller effect sizes [1, 13, 14] . The approach, however, yielded very limited success. Only a handful achieved sufficient statistical significance in replication studies because most reported findings failed to replicate for a variety of reasons that included issues in study design, small sample sizes, and ineffective choice of variants for testing, often driven by insufficient evidence. The collective failure of the candidate gene approach taught us the importance of robust replication, which together with the scaling of studies established a critical foundation for success, namely, adequate power to conclusively detect common variants.
Principles of Cancer GWAS
As the draft sequence of human genome was completed, its annotation revealed a wide spectrum of genetic variation and led to international efforts to study different types of genetic variation in distinct populations [15] [16] [17] [18] [19] . In particular, the HapMap and 1000 Genome Projects provided the comprehensive annotation of SNPs and their correlation, thus enabling investigators to search indirectly for markers that subsequently would be mapped to determine the underlying variants that could explain the biological basis of the signal [19, 20, 21•] . Further advances in microarray technologies have enabled researchers to interrogate hundreds of thousands of SNPs in parallel. Looking across the genome at one time, in an agnostic manner, has given rise to the age of GWAS.
So far, common susceptibility alleles have been discovered by association studies, which compare allele frequencies between affected and unaffected individuals (Fig. 2) . To test for unbiased genome-wide associations, commercial SNP microarrays are designed to tag common variants across the entire genome and as a consequence detect surrogates of the "functional" variant in linkage disequilibrium (LD) and rarely determine the actual functional variant [22] . Interestingly, in some cases, the backbone of a common haplotype may also be a marker for less common variants accounting for the This illustrates the distribution of susceptibility alleles as well as the feasibility of identifying variants through GWAS and sequence analysis signal, known as a Bsynthetic^association [23] ; so far, this scenario has been less frequently encountered than originally postulated. To circumvent false-positive statistical findings, the community has embraced a threshold of genome-wide significance for reporting GWAS results, defined as a trend association test with a p value≤5×10
. Replication in independent sets is important against the pursuit of false positives, since the downstream mapping and laboratory investigation are costly with respect to time and resources [24, 25] . In addition, follow-up studies or large meta-analyses can be effective to conclusively establish GWAS finding [26] .
Cancer GWAS Discoveries
Over 450 distinct genetic loci, marked by one or more highly correlated SNPs, have been conclusively identified for more than two dozen different cancers at or below the threshold for genome-wide significance [27] [28] [29] [30] [31] [32] including common cancers, such as breast, colon, and prostate as well as rarer pediatric cancers, and cancers in young adults, like Ewing sarcoma, neuroblastoma, osteosarcoma, and testicular cancer [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . So far, the reported cancer GWAS findings are almost exclusively restricted to susceptibility to cancer and only with rare exception associated with clinical outcomes, such as metastatic disease or survival. These rare instances have arisen from detailed biological follow-up and been concentrated in a rare pediatric cancer, neuroblastoma; susceptibility loci, such as LMO1, HACE1, and LIN28B, are associated with more advanced disease and survival [44••, 45••] . Additionally, a variant present in the 5' UTR of SLC39A6 disturbs a transcriptional repressor-binding site and results in upregulation of SLC39A6 expression, a risk factor for survival of esophageal squamous carcinoma in East Asia. In turn, overexpression of SLC39A6 correlated with shorter length of survival in individuals with advanced esophageal squamous cell carcinoma [46] . Still, in aggregate so far, the lack of correlation between associated loci and clinical outcomes suggests that distinct regions of the genome may contribute to the development of cancer but not necessarily the progression of cancer. In breast cancer, with large data sets, there is emerging evidence that a small subset of alleles influencing risk might also be associated with survival [47, 48] . The overall discrepancy between etiology and outcome markers may reflect different pathways but also could be, in part, due to study-specific factors that have made GWAS of survival and other clinical outcomes more difficult (e.g., sufficient number of case/events, the length of postdiagnosis follow-up, challenges finding replication population, and quality of phenotype/clinical data). Of interest, another study identified one new locus (rs2059614 at 11q24.2) associated with survival in ER-negative breast cancer cases and did reach genome-wide significance [49] .
To date, the majority of the GWAS markers discovered display large minor allele frequencies (MAF), namely, greater than 10 % and in the first set of studies with adequate power identified larger estimated per-allele odds ratios, in the range of 1.2 to 1.4, but with large-scale consortia, ratios can be discovered in the range of 1.1 [41] . Notably, the pediatric cancer GWAS estimates of 1.6-1.8 were discovered in smaller sample sets and perhaps suggest that the early onset cancers could be a consequence of alleles with stronger effects, in combination with other alleles or exposures. A notable disease is testicular cancer, in young adults, for which the discovery rate has been faster than other cancers, and interestingly, nearly all of the discovered loci have clustered around genes Fig. 2 Genetic analysis of genome-wide association study. Multiple steps are conducted that include the choice of SNPs across genome (usually included on a commercial SNP microarray based on linkage disequilibrium in a region, enabling a surrogate to test for the region). Association analysis is conducted in casecontrol setting, examining all SNPS in a BManhattan plotf ollowed by replication analyses that pinpoint markers on chromosomes that are finemapped and investigated in the laboratory critical for sexual development, telomerase stability, and germ cell development, all key pathways in testicular cancer development. This is not surprising since testicular cancer has a high heritability in family studies, and other identified testicular cancer susceptibility loci have higher per-allele odds compared to other cancer types [36] [37] [38] [39] [40] [41] [42] [43] . Moreover, one of the first loci to be discovered, KITLG on chromosome 12q22, has a per-allele effect estimate greater than 2.5, which could be considered for genetic counseling [37, 38] . TP53 binding in the KITLG gene is under selection and also associated with hair color [50, 51, 52 ••].
Pleiotropy in Cancer GWAS
So far, most susceptibility alleles discovered for cancer risk are specific to one type of cancer. However, there is a small fraction, less than 10 % overall, that appears to be shared by two or more distinct cancers. When two or more cancers map to the same susceptibility allele, this is known as pleiotropy and it these Bshared^regions that provide new insights into potentially common underlying mechanisms. Moreover, there can be an overlap with other complex traits, such as hair color, nevus formation, or obesity, all traits associated with risk for specific cancers, whereas in select circumstances, the shared signal may be a novel or previously underappreciated association between with other risk factors or non-cancer chronic diseases. One variant (rs12821256) approximately 350 kb upstream of KITLG was recently associated with blond hair [50] , while several variants within the KITLG locus were previously reported to be associated with testicular cancer [37, 38] . Furthermore, KITLG plays a role in determining level of pigmentation [51] and has undergone strong positive selection in the European populations [37, 52••] .
The catalog of loci displaying pleiotropy continues to increase, particularly as the progress of GWAS includes larger international consortia. One of the first regions to be discovered was 8q24 for prostate cancer susceptibility, and over time, subsequent studies have expanded the catalog to include multiple independent regions associated with prostate cancer risk, some specific to populations of specific ancestry, such as men of African ancestry [53] . At the same time, this region centromeric to the MYC oncogene on 8q24 harbors at least five distinct, independent loci, some of which are shared between two or more cancers; interestingly, these susceptibility loci include cancers of disparate embryological and mutational spectra, chronic lymphocytic leukemia, breast, colon, bladder, ovarian, and prostate cancers [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] . The mechanism by which each of these loci contributes to susceptibility is complex but appears to be mediated through enhancer regulation of MYC expression [64] [65] [66] . Not surprisingly, cancers with an established viral etiology, such as cervical, liver, nasopharyngeal, and multiple subtypes of non-Hodgkin's lymphoma, have mapped susceptibility loci to the complex HLA region on chromosome 6p21 [67] [68] [69] [70] [71] [72] [73] . Further studies are needed to precisely map the different alleles to understand how class I and class II alleles contribute differentially to cancer risk.
One region which harbors the telomerase gene, TERT, and a close neighbor, CLPTM1L, on 5p15.33 is particularly interesting because it harbors susceptibility loci for at least ten distinct cancers as well as rare mutations associated with dyskeratosis congenita, idiopathic pulmonary fibrosis, acute myelogenous leukemia, and chronic lymphocytic leukemia [42, [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] . Notably, more than ten cancers map to as many as six distinct and independent loci and in each of the six, between three and five cancers, mapped to each independent locus with interestingly both risk-enhancing and protective effects [83] . For example, there is a surprising, inverse relationship for one of the TERT-CLPTM1L alleles between basal cell carcinoma and melanoma, two cancers of the skin strongly associated with sun exposure-one is protective while the alleles confer susceptibility to the other [91] . For a subset of SNPs, an allele-specific effect on DNA methylation was observed, indicating that methylation and subsequent effects on gene expression may contribute to the biology of risk variants of the TERT-CLPTM1L locus [83] . The extensive pleiotropy across the TERT-CLPTM1L locus suggests complex genegene or gene-environment interactions.
The 9p21 region has been implicated in the pathogenesis of multiple cancers and other complex traits such as intracranial aneurysm, coronary artery disease, and type 2 diabetes [92] [93] [94] [95] [96] [97] . This region harbors the cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) and CDKN2B-AS1 genes. In a variety of tumors, somatic mutation and/or deletions have been observed in this same region [98] [99] [100] . Two coronary artery disease risk alleles of SNPs rs10811656 and rs10757278 are located in an enhancer and disrupt a binding site for STAT1, while binding of STAT1 inhibits CDKN2B-AS1 expression in lymphoblastoid cell lines. Using a new, open-ended approach to detect long-distance interactions, in human vascular endothelial cells, the enhancer interval containing the CAD locus physically interacts with among others the CDKN2A/B locus, influencing expression [95] . In different cancer types tested, two risk alleles were associated with cis-expression of 9p21 genes in corresponding cancer tissues in the expression quantitative trait loci analysis [93] .
Meta-Analysis, Pathway Analyses, and Further Discovery of Cancer Susceptibility Loci by GWAS GWAS are scalable for discovery to detect common markers with smaller effect sizes; several studies have increased sample size by comparing newly genotyped cases against previously genotyped or employed large meta-analyses and followup studies. For example, the Collaborative Oncological GeneEnvironment Study (COGS) had pooled existing scans and conducted large-scale replication using a custom Illumina iSelect genotyping array (the iCOGS array) that includes 211, 155 cancer-related SNPs. They found 70 new susceptibility loci for breast, ovarian, and prostate cancers with effects sizes between 1.05 and 1.15 [101] [102] [103] . Since GWAS genotyping has been performed with different commercial and more recently custom SNP microarrays, techniques for imputation of data have been developed, to effectively combine genotyping data across platforms. Imputation programs can successfully infer untested and highly correlated SNPs based on reference data sets, such as the International HapMap Project, the 1000 Genome Project, the Genome of the Netherlands (GoNL) Project, or the DCEG imputation set [18, 19, 
New consortia, such as The Genetic Associations and Mechanisms in Oncology (GAME-ON), have assembled large sets of cases and controls, drawn from a myriad of study designs, and promise to accelerate the discovery of new loci [107, 108] , primarily those loci with estimated effect sizes that are in the range of 1.1. The large, systematic analyses of tens of thousands of cancer cases will yield new loci and provide more data on the polygenic nature of common cancers, such as breast, colon, lung, ovarian, and prostate cancers. In this regard, it is critical to continue this effort to discover the full set of common variants that explain a substantial fraction of the underlying genetic architecture of each of these five common cancers. Park et al. analyzed existing GWAS data to develop a model based on empirical data to estimate the fraction of heritability explained by SNPs for common cancers (breast, prostate, and colon) based on an upper limit for heritability of roughly twofold. Based on the empirical data and model applied, the expected area under the curve is not expected to exceed 0.80 for breast, colon, and prostate, suggesting that additional uncommon variants further explain risk [109, 110] .
Early in the discovery era of GWAS, many investigators postulated that pathways of known genes could harbor susceptibility SNPs that cumulatively could explain risk for cancers, especially in cancers in which modifiable risk factors had been established. To achieve the power needed to detect common markers with smaller effect sizes, Gene Set Enrichment Analysis (GSEA) methods were introduced to GWAS studies, yet the studies to date have not yielded many novel, reproducible findings, mainly because heterogeneity in design and inadequate sample sizes needed have undermined this hopeful approach. While addressing the association of gene sets that share common biological functions, these types of analyses focus on the combined effects of many loci, each making a small contribution to overall disease susceptibility [111] [112] [113] . The problematic assumption has been that the associated SNPs necessarily regulate or alter the nearest, Bplausible candidate gene,^an assumption that has not necessarily been supported by the emerging data in functional studies. In some cases, the effect can be at a distance and not necessarily exerted at the nearest, Bfavorite^gene.
For breast cancer, which has been epidemiologically linked to hormones, very few GWAS signals so far map to regionharboring estrogen/progesterone-related genes [114] . Of interest, in two different breast cancer GWAS data sets, the growth hormone signaling pathway was found highly enriched with association signals employing pathway analysis [115, 116] . GWAS of testicular cancer have identified a number of regions harboring plausible candidate genes, involved in the development of the testes [36] [37] [38] [39] [40] [41] [42] [43] . Deletions of one of these genes, DMRT1, leads to male-to-female sex reversal, and this prompted analysis of a custom-built sex determination gene set using pathway-based analysis in three individual GWAS data sets of testicular cancer. With the exception of DMRT1, none of the genes were previously identified as susceptibility loci in any of the GWAS data sets [117] . Many other groups have used pathway-based approaches to test whether a group of genes in the same functional pathway are jointly associated with disease, but these studies remain preliminary-waiting for independent studies and laboratory confirmation [118] [119] [120] [121] . Although most pathway analysis algorithms adjust for characteristics that may confound observed gene set associations such as LD patterns, gene size, and variant number [111] [112] [113] , it is still important to replicate findings in independent data sets.
It is also important to note that in GWAS of sufficiently large data sets, such as breast cancer and lung cancer, it has been possible to identify loci that map to one subtype and not another one. For example, in breast cancer, there are recent reports of loci that are estrogen receptor-negative only [122] , whereas the vast majority of signals are seen predominately in women with estrogen receptor-positive disease [102] . Interestingly, of the more than 100 prostate loci, perhaps a handful could be associated with only aggressive disease [107, 123] .
Investigation of GWAS Signals In Silico Fine Mapping
To understand the biological underpinnings of each susceptibility alleles, a series of analyses must be undertaken. Each associated region will require extensive resources to conduct fine mapping of possible variants, in silico prediction and prioritization, and the functional studies that provide biological plausibility. Associated regions need to be fine-mapped to determine optimal variants for functional analyses, especially since most associated SNPs are Bindirect^markers for the actual susceptibility alleles; hence, many associated SNPS are observed, but very few actual independent loci have been reported. Fine mapping has been accelerated by the 1000 Genome Project, augmented by the International HapMap, which established a genome-wide framework of common haplotypes. More recently, exome sequencing databases have also provided additional variants, often less common coding variants [124, 125] . To enhance accuracy, some investigators have employed regional resequencing or a custom array to augment the public databases to fully characterize the comprehensive portrayal of both common and rare variants [126] [127] [128] [129] . In some setting, a combination of reference samples genotyped on multiple chips, such as the DCEG imputation set or the haplotypes from GoNL, can increase the accuracy of the 1000 Genome Project imputation, particularly for common variants with minor allele frequencies estimated to be more than 2-3 % [104•, 105•] . The pattern of LD, often with apparent differences between ancestral populations, can be used to further narrow the window for possible direct association of variants. In admixed individuals (e.g., African, East Asian, or Latino/admixed), it is possible to search for admixture markers that might explain differences in disease disparity among different ethnic groups [53, 130, 131] . The comparison of mapping studies in distinct populations should narrow the candidate variants for laboratory evaluation designed to provide laboratory insights into the underlying mechanism(s).
In Silico Assessment of Putative Functional Elements
So far, only a handful of the cancer GWAS signals have been mapped to a coding change in a plausible candidate gene and had subsequent supportive, functional data. While over 90 % of the variants discovered, for cancers and other traits, are mapping t o non-coding regions [31, [132] [133] [134] [135] . Approximately one quarter of variants found through GWAS even map to intergenic regions, in which there are no adjacent correlated markers that map to characterized genes [28] [29] [30] . It is likely that variants present in these non-coding regions do not alter protein coding but play a regulatory role. A greater than expected fraction of cancer susceptibility alleles map to regulatory regions, suggesting that common variants confer susceptibility primarily through perturbations in regulatory events [27, 41, 136] . Indeed, it has been observed that disease-associated SNPs are more likely to have an effect on gene expression than randomly chosen SNPs [137] [138] [139] . For instance, half of the known risk alleles for estrogen receptorpositive breast cancer are expression quantitative trait loci (eQTLs) acting upon major determinants of gene expression in tumors [140•] , though one has to keep in mind that SNPs might not exert a similar effect in different cell or tissue types.
Several public data sets such as The Cancer Genome Atlas (TCGA-adult cancers) project [141] , the Therapeutically Applicable Research to Generate Effective Treatments (TARGET-pediatric cancers) project [142] , and the Genotype-Tissue Expression project (GTEx-normal tissue) [143] have begun to collect a comprehensive catalog of gene expression and regulation across tissues. These data sets will enable studies of eQTLs, alternative splicing, and the tissue specificity of gene regulatory mechanisms and thus might aid in short listing plausible functional/causal SNP markers. In addition, the NIH Roadmap Epigenomics Mapping Consortium (Roadmap-normal tissues and stem cells) [144, 145] and the Encyclopedia of DNA Elements (ENCODE-cell lines) Project [146•] have begun to map DNA methylation, histone modifications, chromatin accessibility, and (small) RNA transcripts, specifically cataloging sign posts and markers of biological activity. Several algorithms, such as Haploreg [147] and RegulomeDB [148] , have incorporated these data sets and are helpful in the bioinformatic assessment and prioritization of potential functional markers.
The clever use of the bioinformatic resources can be informative and lead to unexpected findings. Initially, the discovery of a region on chromosome 19q13.13 associated with chronic infection with hepatitis C virus (HCV), a risk factor for liver cancer, was thought to be related to a nearby gene, IL28B, but the marker SNP is strongly correlated with a dinucleotide variant that Bcreates^a new gene, IFLN4, encoding the interferon lambda4 protein [149••] . Functional studies have shown this new gene and its expression account for the signal; the dinucleotide variant is also a probably risk marker for response to HCV treatment and outcome [150] . The strength of the estimated effect size for spontaneous and treatment-induced clearance of HCV is significantly larger than most cancer GWAS signals, suggesting a possible utility in the clinic.
Laboratory Investigation of GWAS Signals
The pursuit of each region is complex and is determined by the unique characteristics of the genomic region, with respect to the number of correlated variants, functional elements, and known biological processes, such as the effect of a plausible candidate gene on growth, spread, or apoptosis. Each potential functional variant has to be studied separately, and a combination of different approaches and tools is required, which explains the markedly slower pace of characterization (Fig. 3) . Employing techniques such as the chromosome conformational capture (3C), SNP promoter/enhancer reporter assays, electromobility shift assay (EMSA), chromatin immunoprecipitation (ChIP), and eQTL for SNPs of interest can reveal possible functional elements, but these screens still require subsequent confirmation [31, 151, 152] , usually in cell lines or tissue analyses.
For instance, Zeron-Medina et al. determined that 86 of the 62,567 cancer GWAS SNPs (including all variants correlated with known SNP markers) reside in genomic regions occupied by p53, using p53 ChIP-seq data. After further in silico testing, they identify a SNP in a functional p53-binding site in the KITLG region, which is associated with testicular cancer as one of the largest risks identified among cancer GWAS. Functional analysis established allele specificity of the ability of p53 to bind to and regulate transcription of KITLG [52••] . After fine mapping by the Breast Cancer Association Consortium, in large case-control studies using the custom iCOGS chip, three statistically independent risk signals within the FGFR2 locus were identified. By using a combination of in silico and functional analysis, they found three putative functional SNPs. ChIP analysis showed that FOXA1 preferentially bound to the risk allele of rs2981578 and was able to recruit estrogen receptor 1 to this site in an allele-specific manner, whereas E2F1 preferentially bound the risk allele of rs35054928. Chromatin conformation capture demonstrated that the risk region was able to interact with the promoter of FGFR2 [129] . Of interest, both FOXA1 and E2F1 are involved in estrogen signaling and are therefore consistent with the finding that the genetic association in the FGFR2 locus is stronger in estrogen receptor-positive disease, with little or no association for estrogen receptor-negative disease [129] . Analysis in a large case-control study of estrogen receptor-positive tumors identified three independent association signals 11q13. The strongest signal maps to a transcriptional enhancer element in which risk allele rs554219 reduces both binding of ELK4 transcription factor and luciferase activity in reporter assays and may be associated with low cyclin D1 protein levels in tumors. Another candidate variant, rs75915166, creates a GATA3-binding site within a silencer element. Chromatin conformation studies demonstrate that the enhancer and silencer elements interact with each other as well as with CCND1 [153] .
Interestingly, one of the bladder cancer GWAS locus has been mapped to the prostate stem cell antigen (PSCA) gene on chromosome 8 [154] . Based on RNA sequencing followed by functional analysis, a promoter SNP, characterized in fine mapping, has been shown to influence mRNA PSCA expression, and the creation of an alternative translation start site leads to increased expression of PSCA on the cell surface [155•] . This difference in expression suggests that the PSCA gene could be a target for therapy, and the actual genotype could predict PSCA protein expression and identify bladder cancer patients, harboring the PSCA variant, who may benefit from immunotherapy with anti-PSCA-humanized antibody, a potential therapy for different cancers. 
Concluding Remarks
The above examples underscore the value of pursuing an understanding the biological basis of a GWAS signal, which could eventually be the foundation for clinical translation, but further studies are needed to enable this goal. More important is the emerging concept that common susceptibility alleles contribute to cancer risk cumulatively, as part of a polygenic model. The evidence points towards each locus providing a small but measured alteration of one or more pathways, usually through disruption or changes in the regulatory elements and not directly through the coding region, a feature of the emerging class of cancer drivers discovered in somatic sequencing and highly penetrant familial cancer syndromes [11•, 156] .
The pursuit of cancer GWAS will continue to discover susceptibility alleles, filling in the comprehensive catalog of susceptibility variants. The successful use of this approach can now be fully turned to investigate pharmacogenomics and outcome analyses, particularly with large studies on the horizon that are well-phenotyped. Very few common susceptibility alleles also influence clinical outcomes, suggesting distinct mechanisms account for risk over time as opposed to the progression of disease. The discovery of many cancer susceptibility alleles by GWAS represents an important transition in the development of integrative scientific collaborations because it relied on a network of epidemiologists, geneticists, and analysts, who have uncovered genetic markers for risk. The challenge ahead lies in the investigation of the underlying biology that can explain the contribution of susceptibility alleles to disease pathogenesis or progression, which, in turn, could lead to more effective strategies for prevention or treatment. There are daunting challenges in quality control of genome sequence data, a substantively larger number of variants for testing, which compounds the challenge of distinguishing true signal from background noise [157] . To define the comprehensive set of uncommon variants (MAF between 0.5 and 5 %), hybrid approaches will be required including both agnostic testing in family and population studies but also laboratory investigation, as demonstrated for two distinct melanoma susceptibility genes, MITF and POT1 [2, [158] [159] [160] .
Future studies should also focus on two major extensions of the GWAS approach, namely, the interrelationship between germline susceptibility alleles and somatic alterations [161] and the utility of common variants for risk stratification, especially for common cancers, for which changes in absolute risk could have a major impact. It is important to emphasize that the susceptibility alleles discovered by cancer GWAS are not yet ready for personal clinical use, but instead, studies are on the horizon that could effectively utilize differences in risk profile for public health measures or recommendations [162] . It is this effort that holds the promise for implementing germline genetics into precision prevention [163] .
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